Revue neurologiqueHumansBendamustine HydrochlorideRituximabMaleFemale
Short-term follow-up of anti-MAG neuropathy patients given bendamustine plus rituximab combination therapy.
N Bezou, P Morel, B Hivert, E Diab, P Merle, C Tard
Published: 202510.1016/j.neurol.2025.09.009
Abstract
INTRODUCTION: Anti-myelin-associated glycoprotein (anti-MAG) IgM antibodies provoke demyelinating neuropathies, which can be particularly disabling. Conventionally, patients with anti-MAG neuropathies were treated with rituximab alone. This study aim…
Preview only. Read the full abstract at the source